HONG KONG – Looking to position itself as the biggest player in the rapidly growing traditional Chinese medicine (TCM) market in China, the TCM arm of Chinese state-owned Sinopharm Group is planning on a $1.3 billion acquisition of an industry rival and the sale of a biotech subsidiary to channel resources to the development of its TCM business, a move that will help consolidate the market.